APA (7th ed.) Citation

Schnittger, S., Bacher, U., Kern, W., Haferlach, T., Hertenstein, B., & Haferlach, C. (2008). A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. Leukemia (08876924), 22(4), 856. https://doi.org/10.1038/sj.leu.2404949

Chicago Style (17th ed.) Citation

Schnittger, S., U. Bacher, W. Kern, T. Haferlach, B. Hertenstein, and C. Haferlach. "A New Case with Rare E6a2 BCR–ABL Fusion Transcript Developing Two New Resistance Mutations During Imatinib Mesylate, Which Were Replaced by T315I After Subsequent Dasatinib Treatment." Leukemia (08876924) 22, no. 4 (2008): 856. https://doi.org/10.1038/sj.leu.2404949.

MLA (9th ed.) Citation

Schnittger, S., et al. "A New Case with Rare E6a2 BCR–ABL Fusion Transcript Developing Two New Resistance Mutations During Imatinib Mesylate, Which Were Replaced by T315I After Subsequent Dasatinib Treatment." Leukemia (08876924), vol. 22, no. 4, 2008, p. 856, https://doi.org/10.1038/sj.leu.2404949.